14 March 2020
: Case report
Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement
Unusual or unexpected effect of treatment, Rare disease
Heidi Mociková1ABDEF*, Hana Malikova2ABBDDEEFF, Michal Holesta2ABDE, Abdulfattah Elturki3ABDE, Vit Campr4DE, Tomas Kozak1ABDEFGDOI: 10.12659/AJCR.921657
Am J Case Rep 2020; 21:e921657
Abstract
BACKGROUND: CNS involvement in Hodgkin lymphoma is rare. Despite various treatment options, median overall survival is only 13 months after diagnosis of CNS involvement in relapsed/refractory HL.
CASE REPORT: A 29-year-old woman with classical HL (mixed cellularity) in clinical stage IIB was treated with multilineage chemotherapy and radiotherapy without achieving a sustained complete remission. Systemic and CNS progression of HL occurred at the age of 32 years and the patient received 2 cycles of brentuximab vedotin with bendamustine alternating with 2 cycles of high-dose methotrexate-based treatment and achieved partial remission. She then underwent autologous stem cell transplantation followed by brentuximab vedotin consolidation. The disease progressed and the patient died 6 months after the last dose of brentuximab vedotin.
CONCLUSIONS: We demonstrated a durable response to brentuximab vedotin-based chemotherapy in a patient with refractory Hodgkin lymphoma with CNS involvement. Prognosis of these patients is poor and new treatment options are needed.
Keywords: Antineoplastic Agents, Central Nervous System, Hodgkin Disease, Adult, Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Central Nervous System Neoplasms, Disease Progression, Fatal Outcome, Hematopoietic Stem Cell Transplantation, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Prognosis, Salvage Therapy, Transplantation, Autologous
SARS-CoV-2/COVID-19
04 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934468
29 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936896
16 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936498
13 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936889
In Press
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936585
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.935885
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934951
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936165
Most Viewed Current Articles
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
09 Feb 2022 : Case report
DOI :10.12659/AJCR.934744
Am J Case Rep 2022; 23:e934744